logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10485808 B1

PDFFull Text
Date of Patent:
Nov. 26, 2019

Filed:

Apr. 02, 2018

Selective progesterone receptor modulators (sprm) and stabilized estrogen level in patient

Applicant:

Bayer Pharma Aktiengesellschaft, Berlin, DE;

Inventors:

Marcus-Hillert Schultze-Mosgau, Nordbahn, DE;

Xinying Chang, Berlin, DE;

Christian Seitz, Zeuthen, DE;

Carsten Möller, Berlin, DE;

Assignee:

Bayer Pharma Aktiengesellschaft, Berlin, DE;

Attorney:

McBee Moore Woodward & Vanik IP, LLC

Primary Examiner:

Yevgeny Valenrod

Int. Cl.
CPC ...
A61K 31/567 (2006.01); A61K 38/09 (2006.01); A61K 31/505 (2006.01); A61K 31/57 (2006.01); A61P 15/00 (2006.01); A61P 5/34 (2006.01); A61P 15/12 (2006.01); A61P 5/36 (2006.01); A61K 31/095 (2006.01); A61K 31/573 (2006.01); C07J 31/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/567 (2013.01); A61K 31/095 (2013.01); A61K 31/505 (2013.01); A61K 31/57 (2013.01); A61K 31/573 (2013.01); A61K 38/09 (2013.01); A61P 5/36 (2018.01); A61P 15/12 (2018.01); C07J 31/003 (2013.01);
Abstract

The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg/mL to 85 pg/mL.

Find Patent Forward Citations

Loading…